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PTrends in Outcomes After Percutaneous
Coronary Intervention for Chronic Total Occlusions
A 25-Year Experience From the Mayo Clinic
Abhiram Prasad, MD, FRCP, FACC,* Charanjit S. Rihal, MD, FACC,* Ryan J. Lennon, MS,†
Heather J. Wiste, BS,† Mandeep Singh, MD, FACC,* David R. Holmes, JR, MD, FACC*
Rochester, Minnesota
Objectives The aim of our study was to examine the trends in procedural success, in-hospital, and long-term outcomes after
percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) over the last 25 years from a single
PCI registry and to examine the impact of drug-eluting stents.
Background The percutaneous treatment of CTO remains a major challenge. Past studies have used variable definitions of
CTO, and there are limited data available from contemporary practice.
Methods We evaluated the outcomes of 1,262 patients from the Mayo Clinic registry who required PCI for a CTO. The pa-
tients were divided into 4 groups according to the time of their intervention: group 1 (percutaneous transluminal
coronary angioplasty era), group 2 (early stent era), group 3 (bare-metal stent era), and group 4 (drug-eluting
stent era).
Results Procedural success rates were 51%, 72%, 73%, and 70% (p  0.001), respectively, in the 4 groups. In-hospital
mortality (2%, 1%, 0.4%, and 0%, p  0.009), emergency coronary artery bypass grafting (15%, 3%, 2%, and
0.7%, p  0.001), and rates of major adverse cardiac events (8%, 5%, 3%, and 4%, p  0.052) decreased over
time. During follow-up, the combined end point of death, myocardial infarction, or target lesion revascularization,
was significantly lower in the 2 most recent cohorts compared with those patients treated before (p  0.001 for
trend). Technical failure to treat the CTO was not an independent predictor of long-term mortality (hazard ratio
1.16 [95% confidence interval 0.90 to 1.5], p  0.25).
Conclusions Procedural success rates for CTO have not improved over time in the stent era, highlighting the need to develop
new techniques and devices. Compared with the prestent era, in-hospital major adverse cardiac events and
1-year target vessel revascularization rates have declined by approximately 50%. (J Am Coll Cardiol 2007;49:
1611–8) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.12.040A
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ahere have been numerous technical and pharmacological
dvances in the field of percutaneous coronary intervention
PCI) since its inception more than a quarter of a century
go. However, the treatment of chronic total occlusion
CTO) remains a major challenge and is a frequent reason
or a patient’s referral for coronary artery bypass surgery
CABG), leading some to refer to it as the “last frontier” of
CI (1). Physicians frequently encounter CTOs in current
ractice; they are found in as many as one-third of patients
ith at least one vessel with 50% stenosis (2), and they
ccount for 10% of all percutaneous revascularization (3).
rom the *Division of Cardiovascular Diseases and †Department of Internal
edicine and Section of Biostatistics, Mayo Clinic and Mayo Foundation, Rochester,
innesota. Dr. Prasad confirms that he had full access to all of the data in the study
nd takes responsibility for the integrity of the data and the accuracy of the data
nalysis.P
Manuscript received September 20, 2006; revised manuscript received November
1, 2006, accepted December 20, 2006.concerted effort is underway to encourage the develop-
ent of novel techniques and devices for the treatment of
hronically occluded coronary arteries (1,4,5).
However, there are limited published data on the short-
nd long-term outcomes after PCI for CTO in contempo-
ary practice. Previous studies on CTO have suggested that
here has been an improvement in procedural success over
ime (6). Comparison between long- and short-term out-
omes to establish temporal trends is difficult because of the
ariable inclusion criteria, definitions of procedural success,
nd clinical end points. These studies may have included
atients with recent myocardial infarction (MI) and are not
ontemporaneous because they lack information on the
nfluence of drug-eluting stents (DES) on the outcomes (3).
hus, the aim of our study was to examine the trends in
rocedural success, in-hospital, and long-term outcomes
fter PCI for CTO during the last 25-years from a single
CI registry and to examine the impact of DES.
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Since 1979, all patients undergo-
ing percutaneous revasculariza-
tion at the Mayo Clinic in Roch-
ester, Minnesota, have been
prospectively followed in a regis-
try. The registry includes demo-
graphic, clinical, angiographic,
and procedural data. Immediate
and in-hospital events are re-
corded, and each patient is
surveyed by telephone using a
standardized questionnaire at 6
months, 1 year, and then annu-
ally after the procedure. All ad-
verse events are confirmed by
eviewing the medical records of the patients followed at our
nstitution and by contacting the patients’ physicians and
eviewing the hospital records of patients followed else-
here.
We identified 1,262 patients undergoing PCI of a CTO
esion; these patients were divided into 4 groups according
o the time of their intervention: group 1, October 1979 to
ecember 1989 (n  169); group 2, January 1990 to
ecember 1996 (n 459); group 3, January 1997 to March
003 (n  482); and group 4, April 2003 to July 2005 (n 
52). Group 1 consisted of patients who principally under-
ent percutaneous transluminal coronary angioplasty alone.
roup 2 consisted of patients from the early stent era in
hom stents were predominantly used as a bailout strategy.
roup 3 included patients from the bare-metal stent (BMS)
ra in whom stenting was the preferred strategy in conjunc-
ion with dual oral antiplatelet therapy. Finally, group 4
onsisted of patients whose PCI reflects contemporary
ractice and includes treatment with DES. Inclusion criteria
ere patients requiring nonemergency PCI to treat a 100%
cclusion of a coronary artery. Patients were excluded if they
uffered myocardial infarction in the 3 months before PCI.
he study was approved by the Institutional Review Board
t the Mayo Clinic and Mayo Foundation.
Definitions used were as follows. The number of diseased
oronary arteries was defined by at least one coronary artery
ith 70% stenosis and 50% stenosis in the others. Patients
ith 50% stenosis in the left main coronary artery were
onsidered to have 2-vessel disease if there was right
ominance and 3-vessel disease if there was left dominance.
ajor adverse cardiovascular events (MACEs) were defined
s one or more of the following: 1) in-hospital death; 2)
-wave myocardial infarction; 3) urgent or emergent
ABG during the index hospitalization; and 4) cerebrovas-
ular accident defined as transient ischemic attack or stroke.
yocardial infarction was diagnosed in the presence of 2 of
he following 3 criteria: 1) typical chest pain for at least 20
in; 2) elevation of creatine kinase (or the MB fraction)2
Abbreviations
and Acronyms
BMS  bare-metal stents
CABG  coronary artery
bypass grafting
CTO  chronic total
occlusion
DES  drug-eluting stents
MACE  major adverse
cardiac events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
TLR  target lesion
revascularizationimes normal; and 3) a new Q wave on electrocardiogram. in-hospital deaths included all deaths during the index
ospital admission. Procedural success was defined as a
eduction of residual luminal diameter stenosis to 50%
ithout in-hospital death, Q-wave MI, or need for emer-
ency CABG. Technical success was defined as a reduction
f residual luminal diameter stenosis to 50% in the
hronic total occlusion segment. Long-term outcome stud-
ed included all-cause mortality, death or any MI, and
eath/MI or target lesion revascularization (TLR). Other
rocedural complications, such as those related to the
ascular access site, were not included in the present
nalysis. Target lesion revascularization was defined as any
ttempted percutaneous or surgical revascularization of the
arget lesion after the initial procedure.
tatistical analysis. Data are presented as the mean  SD
r as a frequency (percentage). Kaplan-Meier methods were
sed to estimate survival curves. Survival was analyzed in all
atients, with follow-up starting on the day of the PCI.
ests for trends across time groups were made using linear
ontrasts of means in a one-way analysis of variance model
or numerical data (with square root transformation for
umber of stents placed), the Armitage trend test for
ategorical data, and linear contrasts of group effects in a
ox proportional hazards survival model for time-to-event
ata. Comparisons between successful and unsuccessful
CIs are made using the Student t test, Pearson’s chi-square
tatistic, the Mann-Whitney rank-sum test, and the log-
ank test for continuous, nominal, ordinal, and survival data,
espectively. Although the data represent a population
ather than a sample, p values are reported as an indicator of
he magnitude of group differences and effect sizes. Cox
roportional hazards survival models were used to estimate
artial hazard ratios. Covariates were selected on the basis of
linical relevance. Nonlinear relationships between the haz-
rd and continuous variables were considered but were
implified to linear without significant change in the model.
issing data were imputed using the aregImpute function
n the Hmisc S-Plus library created by Harrell. All but 2 of
he variables in the regression model had less than 6.6%
issing values. Ejection fraction was missing in 37%.
hronic renal failure was missing in 33%, predominantly
esulting from the fact that the variable was not recorded in
he registry before 1993.
esults
aseline characteristics. The clinical characteristics of pa-
ients in the 4 groups are summarized in Table 1. The mean
ge and proportion of each gender were similar during the
ime periods. However, there has been a progressive increase
n the prevalence of diabetes mellitus, hyperlipidemia, hy-
ertension, congestive heart failure, and ejection fraction
40% over the course of time. A history of revascularization
oubled from the nonstent era to the stent era and has been
airly steady since. The body mass index of the patients also
ncreased steadily, but the frequency of active smokers
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April 17, 2007:1611–8 PCI for Chronic Total Occlusionsiminished. Chest pain remained the predominant indica-
ion for PCI, but a positive stress was a more common
ndication in the recent cohorts. The prevalence of severe
ngina and unstable angina decreased over time.
ngiographic and procedural characteristics. Table 2
ummarizes the angiographic and procedural characteristics.
here was no significant difference in the prevalence of
ingle versus multivessel disease or the distribution of the
arget vessel treated among the groups. The number of
tents used remained similar over the most recent 2 time
eriods, although glycoprotein IIb/IIIa inhibitor use de-
lined in the recent period (p  0.019 for comparison
etween the 2 most recent cohorts). Procedural success rate
as 51% in the earliest cohort, increasing to 72% for
atients treated between 1990 and 1996, but did not
ignificantly improve (73% and 70%, respectively) in the 2
ost recent time periods. Technical success rate were 54%,
aseline Clinical Characteristics
Table 1 Baseline Clinical Characteristics
Variable, n (%)
1979 to 1989,
n  169 (%)
19
n
Age, yrs 61.9 10.4
Male gender 129 (76)
Diabetes 22 (13)
Hypertension 66 (40)
History of cholesterol 240 mm Hg 58 (41)
Smoking status
Never 62 (37)
Former 78 (46)
Current 28 (17)
Unstable angina 122 (72)
Canadian Cardiovascular Society class III or IV angina 125 (74)
Indication for PCI
Chest pain 158 (93)
CHF 1 (1)
Arrhythmia 4 (2)
Asymptotic 1 (1)
Positive stress test 5 (3)
Other/unknown 0 (0)
CHF status
Never 161 (96)
Previous 1 (1)
Current 6 (4)
Body mass index, kg/m2 28.6 4.4
Prior MI 46 (27)
Prior PTCA 20 (12)
Prior CABG 15 (9)
Peripheral vascular disease
CVA/TIA
Mod/severe renal disease
Ejection fraction
40% 122 (72)
40% 8 (5)
Not available 39 (23)
he p values are test for trend across time periods. Data on peripheral vascular disease, CVA/TIA
CABG  coronary artery bypass grafting; CHF  congestive heart failure; CVA  cerebrovascula
ransluminal angioplasty; TIA  transient ischemic attack.6%, 75%, and 74%, respectively. tutcomes. In-hospital mortality decreased over time (p 
.009) (Table 3). There was a trend toward a reduction in
ny periprocedural myocardial infarction (p  0.081), but
here was no change in rate of Q-wave MIs (2% to 3%)
mong the 4 groups. There was a dramatic reduction in the
eed for emergency or urgent CABG from the first to the
econd time periods (15% and 3%), which continued to
ecrease over time (p  0.001). There was a borderline
ignificant trend toward lower MACE rates over the course
f time (p  0.052). The incidence of cardiac tamponade
as held steady at 1%.
Median follow-up (interquartile range) was available for
16 (197, 230), 134 (112, 158), 63 (47, 84), and 12 (7, 20)
onths, respectively, for the 4 groups. During follow-up,
here was no significant difference in the mortality rates
p  0.84 for comparison between group). There appeared
o be a reduction in the combined endpoint of death or MI but
1996,
9 (%)
1997 to March 2003,
n  482 (%)
April 2003 to July 2005,
n  152 (%) p Value
11.1 64.0 11.6 63.3 12.0 0.19
(77) 360 (75) 113 (74) 0.77
(18) 114 (24) 42 (28) 0.001
(51) 292 (62) 104 (71) 0.001
(56) 342 (77) 125 (86) 0.001
0.32
(35) 172 (36) 60 (41)
(48) 247 (51) 69 (47)
(17) 61 (13) 17 (12)
(69) 318 (66) 78 (51) 0.001
(64) 289 (60) 71 (47) 0.001
0.001
(89) 414 (86) 108 (71)
(1) 5 (1) 5 (3)
(2) 7 (1) 3 (2)
(0) 4 (1) 4 (3)
(7) 44 (9) 25 (16)
(0) 8 (2) 7 (5)
0.005
(93) 408 (90) 124 (86)
(4) 18 (4) 3 (2)
(4) 28 (6) 18 (12)
4.4 29.6 5.5 30.1 6.0 0.009
(41) 162 (34) 43 (30) 0.007
(25) 147 (30) 48 (32) 0.001
(18) 81 (17) 28 (18) 0.034
(9) 31 (7) 6 (4) 0.21
(6) 46 (10) 11 (7) 0.23
(5) 11 (2) 10 (7) 0.028
0.001
(51) 261 (54) 79 (52)
(4) 47 (10) 24 (16)
(45) 174 (36) 49 (32)
nal disease were not recorded in the registry before 1993.
nt; MI  myocardial infarction; PCI  percutaneous coronary intervention; PTCA  percutaneous90 to
 45
62.9
355
82
229
232
159
220
79
317
292
410
5
7
2
34
1
421
18
16
28.9
184
117
84
19
13
10
235
17
207
, and rehis did not reach statistical significance (p  0.16) (Fig. 1).
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PCI for Chronic Total Occlusions April 17, 2007:1611–8he combined end point of death, MI, or TLR was
ignificantly lower in the 2 most recent cohorts compared
ith those patients treated before 1997 (p  0.001 for
rend) (Fig. 1). At 1 year, the respective event rates for the
ombined end point were 36%, 37%, 26%, and 21% in the
groups of patients. The rates of TLR in the 4 groups were
6%, 24%, 13%, and 11% at 6 months and 28%, 29%, 17%,
nd 14%, respectively, at 1 year (p  0.001). Percutaneous
LR rates at 6 months were 6%, 14%, 7%, and 6% at 6
onths and 7%, 18%, 10%, and 8% at 1 year, respectively
p  0.017 for trend in last 3 groups).
echnical failure. There were no significant differences in
he age, gender, presenting symptom, history of diabetes
ellitus, hyperlipidemia, hypertension, congestive heart
ailure, peripheral vascular disease, cerebrovascular disease,
revious PCI or CABG, single versus multivessel disease,
nd ejection fraction between patients who did and did not
ave technically successful procedures. A history of MI and
moking was more frequent in those with unsuccessful PCI
Table 4). In-hospital death and MI were not significantly
ifferent based on PCI technical success; CABG, however,
as significantly greater (11% vs. 1%) in unsuccessful
rocedures (Table 4). Long-term mortality was significant
reater in patients with technical failure (p  0.025) (Fig. 2),
lthough the separation in curves is not distinct until after 6
ngiographic and Procedural Characteristics
Table 2 Angiographic and Procedural Characteristics
Variable, n (%)
1979–1989,
n  169 (%)
1990–1996,
n  459 (%)
Number of vessels diseased
Single 45 (28) 134 (31)
Double 67 (42) 166 (38)
Triple 49 (30) 141 (32)
Total number of stents placed 0.0 0.0 0.5 1.1
Drug-eluting stent use
GP IIb/IIIa use 39 (8)
Vessel treated
Right coronary artery 54 (32) 168 (37)
Left anterior descending 59 (35) 175 (38)
Circumflex artery 57 (34) 120 (26)
Procedural success 87 (51) 331 (72)
Technical success 91 (54) 347 (76)
Cardiac tamponade 3 (1.4)
he p values are test for trend across time groups.
GP  glycoprotein.
n-Hospital Outcomes
Table 3 In-Hospital Outcomes
Variable
1979–1989,
n  169 (%)
1990–1996,
n  459 (%)
Death 4 (2.4) 6 (1.3)
Any myocardial infarction 17 (10) 41 (9)
Q-wave myocardial infarction 4 (2.4) 9 (2.0)
CABG 26 (15) 16 (3)
MACE 13 (8) 21 (5)he p values are test for trend across time groups.
CABG  coronary artery bypass grafting; MACE  major adverse cardiac event.ears. When using multivariate analysis, we determined that
echnical failure was not an independent predictor of mor-
ality (hazard ratio 1.16 [95% confidence interval 0.90 to
.5], p  0.25). Table 5 shows the covariates used for
djustment. Age, diabetes mellitus, history of smoking,
istory of congestive heart failure, ejection fraction, triple-
essel disease, chronic renal failure, and the date of the
rocedure were independent predictors of mortality during
ollow-up.
iscussion
he major findings of the present study are that, during the
ast 25 years, among patients requiring PCI for the treat-
ent of a CTO: 1) the procedural success rate in the stent
ra has held steady at approximately 70%; 2) there has been
progressive reduction in periprocedural major adverse
vents; 3) survival and myocardial infarction rates during
ollow-up were not significantly different; and 4) there has
een a progressive reduction in the need for target vessel
evascularization, a trend that that appears to be continuing
n the DES era.
rocedural success rates. Our study illustrates the trends
n procedural success rates for CTO from the time PCI was
rst introduced as a treatment for coronary artery disease
1997 to March 2003,
n  482 (%)
April 2003, to July 2005,
n  152 (%) p Value
0.37
112 (25) 47 (36)
192 (43) 43 (33)
143 (32) 40 (31)
1.7 1.5 1.5 1.3 0.001
107 (70)
258 (54) 65 (43) 0.001
179 (37) 58 (38) 0.62
177 (37) 55 (36) 0.89
134 (28) 41 (27) 0.30
354 (73) 107 (70) 0.001
363 (75) 112 (74) 0.001
4 (0.8) 2 (1.3) 0.88
1997 to March 2003,
n  482 (%)
April 2003 to July 2005,
n  152 (%) p Value
2 (0.4) 0 (0) 0.009
39 (8) 7 (5) 0.081
12 (2.5) 5 (3.3) 0.48
8 (1.7) 1 (0.7) 0.001
16 (3.3) 6 (3.9) 0.052
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April 17, 2007:1611–8 PCI for Chronic Total Occlusionshrough to contemporary practice. We observed that, in the
restent era, successful revascularization was achieved in
pproximately one-half (51%) of the patients. Procedural
uccess rates increased sharply to approximately 70% from
990 onward, almost certainly as the result of the introduc-
ion of stents. However, more widespread use of stents and
dvances in their design has not been associated with further
mprovement in procedural success. These findings are
onsistent with previous individual studies published during
ifferent time periods (3,6–15). Suero et al. (6) reported an
verall procedural success rate of 69.9% in their cohort
uring the period of 1980 to 1999 in which 7% of patients
ere treated with a stent. In more recent time periods,
livari et al. (15), as well as Hoye et al. (3), have reported
rocedural success rates of 73.3% and 65.1%, respectively,
mong patients who were predominantly (80%) treated
ith stents. In current practice, the predominant reason for
he low success rate in the treatment of CTO is the failure
o cross the lesion (16), highlighting the need for developing
ew devices and techniques for tackling this lesion subset
1,4,5). Moreover, our data suggest that advances in guide-
ire technology during the most recent time period are yet
o have a major effect on procedural success rates, although
Figure 1 Long-Term Outcomes
Kaplan-Meier estimates for (A) death, (B) death or myocardial infarction, and (C)
The sudden survival decrease around 8 years for the 1997 to March 2003 group
and reflects the instability of the estimator when few patients remain. However, w
of the 2 earliest groups.ontinued surveillance is required to establish their full 1mpact. In addition it is possible that their efficacy is, in part,
egated by the use in increasingly complex lesion morphol-
gy. Regardless, our findings challenge the notion that there
as been a progressive improvement in success rates in the
tent era (4).
linical outcomes. As with other lesion subsets, there has
een a steady decrease in in-hospital death associated with
CI over time, with mortality rates being 0.5% in the
tent era. Similarly, there has been a progressive decrease
p  0.08) in postprocedural MI with a rate of 5% in our
ost recent cohort of patients. In contrast, the frequency of
arge (Q-wave) infarcts has not decreased during the last 25
ears, emphasizing the fact that there is potential for harm
ven when treating occluded vessels. Myocardial ischemic
njury may result from damage to the collateral circulation,
ranch vessel occlusion, or distal embolization. The im-
rovement in outcomes have occurred despite the patients
n the recent cohorts having more adverse clinical charac-
eristics such as diabetes and reduced ejection fraction,
eflecting the improvement in PCI techniques and adjunc-
ive therapy. In addition, there has been a major reduction
n the need for urgent CABG after PCI, with the greatest
hange coinciding with the introduction of stents in the
myocardial infarction (MI), or target lesion revascularzation in the 4 groups.
e result of an event occurring among a small number of patients still at risk
ent the curves to 10 years for the benefit of comparing the 10-year estimatesdeath,
was th
e pres990s. The current rate of 0.7% is similar to the frequency
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PCI for Chronic Total Occlusions April 17, 2007:1611–8f urgent CABG reported in our larger patient population
rom the Mayo PCI registry (17).
The long-term mortality and the combined occurrence of
eath or MI did not change over time. Survival at 2 years
as approximately 95% in all 4 cohorts and remained
imilar out to 10 years’ follow-up. Thus, the improvement in
rocedural success rates in the stent era did not appear to
onfer a long-term survival benefit after PCI. However, this
nding needs to be evaluated, bearing in mind that PCI has
Figure 2 Technical Success and Survival
Kaplan-Meier estimates for death among patients with
haracteristics and In-Hospitalutcom s of Patients Ba ed on Procedural Success
Table 4 Characteristics and In-HospitalOutcomes of Patients Based on Procedural Success
Variable, n (%)
Technical
Failure,
n  348
Technical
Success,
n  914 p Value
Patient characteristics
Age, yrs 63.7 11.3 63.1 11.4 0.40
Male gender 260 (75) 697 (76) 0.57
Prior MI 143 (42) 292 (33) 0.002
Smoking status 0.045
Never 113 (33) 340 (38)
Former 172 (50) 442 (49)
Current 61 (18) 124 (14)
Ejection fraction 0.43
40% 186 (53) 511 (56)
40% 28 (8) 68 (7)
N/A 134 (39) 335 (37)
Number of vessels diseased 0.24
Single 84 (26) 254 (30)
Double 131 (41) 337 (39)
Triple 108 (33) 265 (31)
In-hospital outcomes
Death 5 (1) 7 (1) 0.27
Any MI 30 (9) 74 (8) 0.76
Q-wave MI 9 (3) 21 (2) 0.76
CABG 39 (11) 12 (1) 0.001
ABG  coronary artery bypass grafting; MI  myocardial infarction.4ot been shown to improve survival in any other lesion
ubset among patients with stable disease and generally is
erformed with the aim of relieving ischemia. Moreover,
he observational design of our study makes it likely that the
reater prevalence of adverse clinical characteristics, such as
iabetes, hypertension, hyperlipidemia, greater body mass
ndex, congestive heart failure, and reduced ejection fraction
mong patients in the recent cohorts would confound the
bility to demonstrate temporal improvement in outcomes
s the result of advances in medical therapy (18). This result
s supported by the observation that the date when the PCI
as performed was an independent predictor of survival in
multivariable model. After adjustment for the differences
n patient characteristics, there was a 4% relative reduction
n mortality per year.
epeat revascularization. There has been a marked reduc-
ion (50%) in the need for TLR from 1997 onward,
oinciding with the widespread use of stents. This finding is
onsistent with several randomized trials that have estab-
ished the efficacy of BMS over balloon angioplasty in
educing angiographic restenosis in CTO by approximately
0% (19–22). Recent data from several registries suggest
hat the use of DES in CTO, as with all other lesion
ubsets, is effective in further decreasing restenosis and the
eed for revascularization when compared with BMS (23–
6). We also observed a trend in reduction in target vessel
evascularization in our DES cohort compared with the
MS cohort. However, this trend did not reach statistical
ignificance, potentially because of the relatively small num-
er of patients in the DES group. Data from a small
andomized trial of 200 patients in the PRISON II (Pro-
pective Randomized Trial of Sirolimus-Eluting and Bare
etal Stents in Patients With Chronic Total Occlusions)
tudy comparing BMS with DES have demonstrated that
he use of DES significantly reduces angiographic restenosis
nd TLR in patients with CTO (27). The rates of target
essel revascularization and TLR at 6 months were 8% and
ox Proportional Hazards Survivalodel Results for Long-Term Survival
Table 5 Cox Proportional Hazards SurvivalModel Results for Long-Term Survival
Variable HR 95% CI p Value
Technical failure 1.16 (0.90–1.50) 0.25
History of congestive heart failure 2.74 (1.87–4.00) 0.001
Age (per 10 yrs) 2.02 (1.75–2.32) 0.001
Chronic renal failure 1.76 (1.01–3.09) 0.048
History of smoking 1.59 (1.22–2.07) 0.001
Diabetes 1.52 (1.12–2.05) 0.007
Triple-vessel disease 1.47 (1.15–1.89) 0.002
Ejection fraction (per 10%) 0.90 (0.82–0.97) 0.008
Procedure date (per 1 yr) 0.96 (0.93–0.99) 0.015
Male 0.78 (0.59–1.02) 0.072
Hypertension 1.08 (0.83–1.40) 0.57
Body mass index (per 5 kg/m2) 0.89 (0.77–1.02) 0.09
Urgent PCI 1.00 (0.71–1.40) 1.00
I  confidence interval; HR  hazard ratio; PCI  percutaneous coronary intervention.technically successful versus unsuccessful interventions.
%, respectively, which is similar to our patients with DES.
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April 17, 2007:1611–8 PCI for Chronic Total Occlusionsecently, the TOSCA-4 (Total Occlusion Study of Can-
da) registry has been established in the U.S. to facilitate
ood and Drug Administration approval for the use of DES
n the treatment of patients with CTO.
mpact of technical failure. As reported previously, pa-
ients who underwent a failed PCI did not have greater
n-hospital death or MI but, not surprisingly, they were
uch more likely to be referred for surgical revascularization
3). We have previously reported that successful recanaliza-
ion of a CTO does not significantly impact long-term
urvival (7). In contrast, several subsequent studies have
ndicated that a successful procedure confers a long-term
urvival benefit (3,6,28). In the present study, patients with
technical success did appear to have slightly greater
urvival at 6 years after PCI, but no immediate survival
dvantage was observed. There are at least 2 potential
xplanations for the association between technical success
nd survival. First, as suggested by others (6), there may be
direct benefit of restoring coronary patency and myocar-
ial perfusion on ventricular function and the risk of life
hreatening arrhythmia. However, this benefit can only be
efinitively evaluated by a randomized trial comparing
ptimal medical therapy with PCI. Alternatively, patients
ho undergo a failed procedure may have more severe
therosclerosis that is associated with fibrosis and calcifica-
ion of the vessels accounting for both technical failure and
igher mortality. Previous studies have reported that tech-
ical failure is more frequent among patients with multives-
el disease (3,6,28). Although this was not observed in our
tudy, patients with failed procedures were more likely to
ave had a previous MI. Furthermore, technical failure was
ot an independent predictor of mortality by multivariable
nalysis. Survival did correlate with left ventricular dysfunc-
ion, and patient attributes associated with greater athero-
clerotic burden, supporting the hypothesis that technical
ailure may be a marker of disease severity.
tudy limitations. Although the data were collected pro-
pectively, this is a retrospective single center analysis and is
ubject to the limitations of such analyses. The precise
uration of the occlusion was not angiographically docu-
ented, a limitation applicable to all observational studies
f CTO. Independent core angiographic laboratory analysis
o investigate lesion characteristics and collateral blood flow
as not performed, which may have provided insight into
he determinants of procedural success and MACE in
urrent practice. The study is limited to patients treated
ith PCI, and we cannot comment on the trends in
utcomes for patients with CTO who are managed with
edical therapy or surgical revascularization.
onclusions
he introduction of coronary stents has resulted in a marked
mprovement in procedural success for CTO, but the rate
as remained around 70% and has not improved during the
ast decade. It is imperative that there is continued focus oneveloping new techniques and devices to improve the
uccess rates. It is encouraging that PCI for CTO has
ecome much safer over time, with MACE rates of 5% in
urrent practice. The use of stents, including DES, has been
ccompanied by a marked reduction in TLR, but there has
een no apparent improvement in the long-term survival of
atients. Thus, we recommend that PCI should primarily be
onsidered for the treatment of angina or extensive myocar-
ial ischemia in patients with CTO.
eprint requests and correspondence: Dr. Abhiram Prasad,
ayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
-mail: prasad.abhiram@mayo.edu.
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